The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Notice of Special Interest: Promoting research opportunities on HIV/AIDS in NIAMS
The purpose of this announcement is to inform potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of an area of special interest in HIV/AIDS-associated comorbidities that are within the NIAMS mission.
The HIV/AIDS pandemic has been a challenging US public health issue. The NIH has provided the largest public investment in HIV/AIDS research globally. In line with overall NIH efforts, NIAMS would like to promote observational, translational, and basic/pre-clinical research focusing on how the presence or treatment of HIV/AIDS impacts systemic rheumatic, musculoskeletal and skin disease progression and pathogenesis with a focus on utilization of existing HIV cohorts and repositories.
Applications should meet the NIH HIV/AIDS Research Priorities and Guidelines: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html. NIAMS is interested in supporting studies focused on, but not limited to:
- delineating the impact of viral or host factors or interaction of these two factors, or anti-retroviral therapy (ART) in people living with HIV (PLWH) on accelerating or worsening or early-onset of comorbidities.
- studying the prevalence and risk assessment and management of HIV/AIDS-associated comorbidities in PLWH.
- identifying etiological targets or biomarkers along with mechanistic action for diagnosis or preclinical candidate therapeutic evaluation/development.
Examples of HIV/AIDS-associated comorbidities that are within the NIAMS mission are:
- Musculoskeletal pain
- Muscle diseases (e.g. Sarcopenia, Cachexia, Muscular dystrophy)
- Cartilage degeneration (e.g. Osteoarthritis)
- Bone diseases (e.g. Osteoporosis, Osteopenia)
- Bone fracture
- Arthritis and other rheumatic diseases (e.g. Reactive arthritis, Psoriatic arthritis, Septic arthritis)
- Dermatological manifestations
This notice applies to due dates on or after December 2, 2019 and subsequent receipt dates through January 10, 2023 (per NOT-AR-22-13)